McKesson’s Next Act: Clinical Trials and Home Infusion

A 41% 90-day run and a raised FY27 guide are the headline; $3.65 billion of new deals are the story.

MCK · Earnings Call · 2026-11-04

The Beat Is Real—and Still GLP-1-Shaped

McKesson’s fiscal Q2 was clean by any distributor standard: revenue rose 8% to $111 billion, adjusted EPS climbed 18% to $11.68, and the company raised FY27 adjusted EPS guidance to $45.60–$46.40 from $44.20–$45. The stock has already voted, rising 41.5% over the last 90 trading days and roughly 42% over 17 weeks. At a $124.6 billion market cap, this is a large-cap re-rating, not a small-cap squeeze. It is also company-specific: the global keyword tape is dominated by AI data centers, tariffs, Fed rates, and election outcomes. McKesson is not riding a market-wide wave; it is riding its own specialty-distribution flywheel. The engine is North American Pharmaceutical, where revenue rose 6% to $91.4 billion and operating profit jumped 22% to $1 billion. GLP-1 distribution revenue was $16 billion, up 26% year over year and 8% sequentially, while prescription volume growth remained the top company keyword. Oncology and Multispecialty revenue rose 24% to $15 billion, with operating profit up 8% to $427 million—23% excluding last year’s $51 million gain. RxTS revenue rose 10% to $1.5 billion and operating profit 18% to $307 million, helped by access solutions. But the quarter was not uniformly strong: MedSurg revenue rose 5% while operating profit fell 10% on ambulatory-care product mix, even as the extended care channel grew. The recurring theme is that McKesson keeps outgrowing its own margin mix. In the prior August call, CFO Kenny Cheung described the same dynamic: “North America pharmaceutical had a really strong quarter for us ... AOP did grow faster than revenue, implying a higher margin mix profile.” — Kenny K. Cheung, Chief Financial Officer · 2026-08-05 That was not a one-quarter anomaly. It is now a pattern. Yet the valuation has not stretched: Price to Gross Profit is 6.1x, down 11% year over year, and Price to Operating Income is 14.0x, down 32% year over year. Earnings are outrunning the shares.

The New Thing: Buying Into Clinical Trials and Home Infusion

What actually changed this quarter was capital allocation. McKesson closed its $2.25 billion cash acquisition of Precision Medicine Group, a two-part business that pushes the company deeper into biopharma services. Brian Tyler framed the strategic logic clearly: “Precision for Medicine ... provides global clinical research, translational science, and laboratory capabilities with deep oncology experience and trials active in more than 30 countries.” — Brian Tyler, Chief Executive Officer · 2026-11-04 The other piece, PrecisionAQ, adds market access, health economics, and commercialization services. PMG will report inside Oncology and Multispecialty, and Cheung sized the accretion: “we estimate the acquisition will contribute approximately $0.10 to $0.20 of adjusted EPS in fiscal ’27, and by the end of year 3, we estimate accretion of approximately $1.60 to $1.80.” — Kenny Chung, Chief Financial Officer · 2026-11-04 Then there is Option Care Health: roughly $1.4 billion for a 49% minority stake, with Clayton, Dubilier & Rice owning the majority and running the business. McKesson will account for it under the equity method, reported in corporate, not in segment margins. That structure is deliberate—it lets McKesson place a strategic bet on home and alternate-site infusion without consolidating the operating risk. Tyler called it a way to

germinate a business outside of the day-to-day operating requirements ... incubating future growth platforms highly adjacent to our core strategy and supporting our long-term growth algorithm well into the future.
Brian Tyler, Chief Executive Officer · 2026-11-04

The keyword community-based provider is not new for McKesson, but the execution is: this is the first time the company has bought a minority stake in a national home-infusion platform as a way to extend its specialty reach. Together, the two deals total roughly $3.65 billion. Both are funded from a balance sheet with $6.5 billion of cash and $11.5 billion of total liquidity, and both are meant to extend the oncology and biopharma-services runway beyond drug distribution. PMG adds clinical-trial infrastructure; Option Care adds a lower-cost care setting. If the thesis works, McKesson becomes less of a pure distributor and more of a specialty-care services platform.

The Tension: A Raised Guide, an Unraised Algorithm

The awkward moment came when Kevin Caliendo of UBS asked whether McKesson’s long-range plan looked “comically low” against 20%-plus North American Pharmaceutical operating-profit growth. Cheung did not budge: “our long-term targets are long-term in nature, not an indicator of short-term variations that incur—that can occur within the business year to year.” — Kenny Chung, Chief Financial Officer · 2026-11-04 That is the central tension. The company raised FY27 guidance but left its long-term 13%–16% EPS algorithm untouched, even though FY27 guidance implies 19%–21% adjusted EPS growth excluding last year’s Norway divestiture and U.S. Oncology gains. Investors are left to decide whether management is conservative or whether GLP-1, 340B, and biosimilar policy risk justify a wider margin of safety. Policy is the obvious overhang. On 340B, Tyler said McKesson does not anticipate a material financial impact, but the prior August call struck a more cautious tone: “this is probably pretty preliminary because the current proposal remains under a comment and review period ... we have seen many 340B proposals come and go.” — Brian S. Tyler, Chair and Chief Executive Officer · 2026-08-05 The difference is tone, not substance—still watching, still hedging. Lower branded pharmaceutical pricing cut North American Pharmaceutical revenue growth by roughly 4% in the quarter, but management again said it had no meaningful operating-profit impact. The GLP-1 Bridge Program is another swing factor: initial demand was strong, but prior-authorization volumes have begun to normalize. And the planned Medical-Surgical Solutions separation is already visible in higher interest expense. The bull case is that McKesson is a cash-generating compounder using its balance sheet to buy into higher-growth, higher-multiple adjacencies while its core distribution business compounds ahead of the market. The bear case is that GLP-1 growth normalizes, 340B reform bites, and the new deals take time to move the needle. For now, the tape is siding with the bull case. The stock’s 41.5% 90-day run says the market believes the flywheel is intact—and that management’s long-term algorithm may soon need a rewrite, even if management will not write it yet.